Agenus (NASDAQ:AGEN) Announces Earnings Results

Agenus (NASDAQ:AGEN – Get Free Report) announced its earnings results on Monday. The biotechnology company reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08), Zacks reports. Agenus had a net margin of 50.49% and a negative return on equity of 29.79%. The business had revenue of $33.70 million during the quarter, compared to analysts’ expectations of $129.50 million.

Agenus Price Performance

Shares of AGEN stock traded up $0.10 during mid-day trading on Wednesday, hitting $3.54. The stock had a trading volume of 131,712 shares, compared to its average volume of 774,776. The firm has a market cap of $135.74 million, a PE ratio of 2.24 and a beta of 1.60. The company’s 50-day simple moving average is $3.72 and its 200-day simple moving average is $3.67. Agenus has a fifty-two week low of $2.71 and a fifty-two week high of $7.34.

Get Agenus alerts:

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. EP Wealth Advisors LLC acquired a new stake in Agenus in the fourth quarter valued at about $31,000. Quadrature Capital Ltd acquired a new position in Agenus during the 4th quarter worth approximately $54,000. Squarepoint Ops LLC purchased a new position in shares of Agenus during the 3rd quarter worth approximately $54,000. Jump Financial LLC purchased a new position in shares of Agenus during the 2nd quarter worth approximately $55,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Agenus in the 1st quarter valued at approximately $58,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on AGEN. Wall Street Zen upgraded Agenus from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Zacks Research cut Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Agenus currently has an average rating of “Hold” and a consensus target price of $14.50.

Check Out Our Latest Analysis on Agenus

About Agenus

(Get Free Report)

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.

See Also

• Five stocks we like better than Agenus
• How Bad Could Tesla’s Cybertruck Recall Be for Shares?
• Dream Finders Homes’ Hostile Bid Creates a Dual Squeeze Play
• Why OpenAI’s IPO Plans Could Be a Massive Win for Microsoft
• A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.